Give every transplant a safer chance
Founded by a transplant survivor advancing HLA-based compatibility modeling to reduce rejection and expand access.
Give every transplant a safer chance
Founded by a transplant survivor advancing HLA-based compatibility modeling to reduce rejection and expand access.
Our story
“I am alive today because of a stem cell transplant from my cousin to treat lymphoma and have remained cancer-free since then (~3 years).”
— Lidio Meireles, PhD | Founder & CEO
“Thanks to a stem cell transplant from my cousin, I am alive today — lymphoma-free for nearly three years. I had a successful mismatched transplant, but many aren’t as lucky.”
— Lidio Meireles, PhD | Founder & CEO
Immunomatics exists to improve donor-recipient matching.
Today's treatments could be safer
Behind every failed kidney transplant is a patient forced back to dialysis, a family restarting the waiting process, and billions in avoidable healthcare costs each year.
Current practice
treats all donor mismatches the same risk, missing key immune details that determine whether a new organ or tissue will be accepted or rejected.
That’s causing preventable failures, longer treatments, and lives put on hold right now.
(within 5 years)
Better matches,
safer transplants
Immunomatics is leveraging advanced AI algorithms and HLA compatibility modeling to assess the risk of donor-recipient mismatches and help clinicians make more precise decisions.
By analyzing transplant outcomes, we aim to identify low-risk mismatches, improve donor selection, and personalize immunosuppression.
Smarter donor selection
Evaluates HLA compatibility beyond simply counting
mismatches.
Personalized care
Supports tailored immunosuppression for safer recovery.
Improved access
Expands viable donor options for underrepresented patients.
Evidence-based insight
Built on real transplant outcomes and with planned clinical validation.
Better matches,
safer transplants
Immunomatics is leveraging advanced AI algorithms and HLA compatibility modeling to assess the risk of donor-recipient mismatches and help clinicians make more precise decisions.
By analyzing transplant outcomes, we aim to identify low-risk mismatches, improve donor
selection, and personalize immunosuppression.
Smarter donor selection
Evaluates HLA compatibility beyond simply counting mismatches.
Personalized care
Supports tailored immunosuppression for safer recovery.
Improved access
Expands viable donor options for underrepresented patients.
Evidence-based insight
Built on real transplant outcomes and with planned clinical validation.
How it works
Immunomatics integrates HLA and non-HLA data from donors, patients, and transplant procedures to estimate the immunological risk of complications.
Modern computational methods
Models learn patterns linked to rejection risk using advanced machine-learning approaches.
Immunobiology-informed design
Model architectures reflect how T and B cells recognize antigens to capture compatibility more precisely.
Multi‑modal evidence
Combines registry outcomes, bioassays, and protein sequences and structures to enhance model performance.
Your opportunity
The need is global. The market is growing.
Your opportunity
The need is global. The market is growing.
Transplantation Risk Assessment Software
$3B TAM
Global pre-transplant diagnostics market
$198M SAM
Pre-transplant risk assessment software
$19M SOM
Targeted market share (NA, EU, APAC)
Allogeneic Cell Therapy Market
$4.6B
projected by 2034
Cell therapies face the same immune barriers as transplants.
Immunomatics’ HLA-matching platform extends naturally to this multi-$B opportunity.
Progress at a glance
Immunomatics is advancing rapidly toward proof of concept with support from NIH funding.
Foundation
Now
NIH-funded development,
SRTR data access,
Collaboration with UCSD’s Immunogenetics & Transplantation Lab.
Execution
Next 12–18 months
Proof of concept,
Pilot programs at transplant centers,
NIH Phase II application ($2M).
Vision
Destination
Regulatory clearance
Expansion across the U.S. and Europe.
Join us in changing transplant outcomes
Get behind the science that improves transplant outcomes with AI-assisted donor-recipient matching.
Join us in changing transplant outcomes
Help us build a future where every transplant has a chance.
Get behind the science that improves transplant outcomes
Connect with Immunomatics
Schedule a conversation with our founder to explore partnership and investment opportunities.
Answers to the questions we hear most
What problem is Immunomatics solving?
Current practice treats all donor mismatches the same risk. Our models aim to identify low-risk mismatches, enhance donor selection, and personalize immunosuppression, thereby improving transplant outcomes.
Who are your primary customers?
Transplant centers, histocompatibility labs, donor registries, and biotech companies working in transplantation or allogeneic cell therapy.
How is your work funded?
Supported by significant founder investment and a $208K NIH SBIR Phase I grant, with additional NIH and CIRM funding applications in progress.
How does AI fit into your work?
We employ advanced AI algorithms and HLA compatibility modeling to learn patterns of rejection risk from clinical outcomes.
How can I get involved or learn more?
We’re seeking mission-aligned investors and partners to accelerate this work. [Book a Meeting →]
Disclaimer: Some information on this page reflects projected timelines and pending funding applications. All statements are accurate as of October 2025
© 2025 Immunomatics, Inc. All rights reserved.